TP-0903 is a potent and selective AXL Inhibitor. TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges. Combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis AXL overexpression is a reoccurring theme observed in multiple tumor types that have acquired resistance to various agents. Treatment of cancer cells with TP-0903 reverses the mesenchymal phenotype in multiple models and sensitizes cancer cells to treatment with other targeted agents. Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.
Axl Inhibitors Related Products:
Cabozantinib; SGI-7079; BMS777607; 2-D08; Gilteritinib; Merestinib; NPS-1034; LDC1267; Bemcentinib